Streetbeat News

Regulatory

QQQ

SPY

The Producer Price Index (PPI) for July showed a slower-than-expected increase, reinforcing disinflationary trends and bolstering expectations for a Federal Reserve rate cut. The PPI rose by 2.2% annually, down from 2.7% in June, and the core PPI remained unchanged month-over-month. This has led to increased market speculation about a potential 50-basis-point rate cut in September. Major U.S. equity futures traded higher, and Treasury yields slightly decreased.

Portfolio Pulse from Piero Cingari

August 13, 2024 | 12:40 pm

MBOT

Microbot Medical has received ISO 13485:2016 certification for its Quality Management System, a significant milestone that demonstrates the company's commitment to quality and regulatory compliance in the medical device industry.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:35 pm

GNPX

Genprex has been granted a patent in Singapore for its Reqorsa gene therapy in combination with PD-1 antibodies, extending protection through 2037. This expands on previously granted patents covering the use of REQORSA with immune checkpoint inhibitors.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:33 pm

ADIL

Adial Pharmaceuticals (NASDAQ:ADIL) announced a collaboration with Boudicca Dx to advance the regulatory strategy for its companion diagnostic genetic test for AD04, a treatment for Alcohol Use Disorder. This collaboration aims to ensure the test meets FDA guidelines and supports the upcoming Phase 3 study.

Portfolio Pulse from Vandana Singh

August 13, 2024 | 12:30 pm

ADIL

Adial Pharmaceuticals has announced that Boudicca will support and advise the company on its companion diagnostic genetic test to ensure compliance with FDA guidelines.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:30 pm

ADIL

Adial Pharmaceuticals has signed an agreement with Boudicca Dx to advance the regulatory strategy for a companion diagnostics genetic test for AD04.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:30 pm

EVLV

Evolv Technology (NASDAQ:EVLV) has been awarded a patent by the USPTO for its unique weapons detection technology used in its flagship product, Evolv Express. This patent, which classifies objects as threats or non-threats using RF electromagnetic data, adds to Evolv's growing portfolio of over 30 issued patents. The technology is deployed in various public spaces globally.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:14 pm

ENVB

Enveric Biosciences and Aries Science & Technology have announced the issuance of a key U.S. patent for a topical product aimed at treating radiation dermatitis. The patent strengthens Enveric's portfolio and is part of a Licensing Agreement between Enveric's subsidiary Akos Biosciences and Aries. The market opportunity for this treatment is estimated at $400 million annually.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:08 pm

GM

General Motors (GM) is recalling nearly 22,000 Cadillac Lyriq electric SUVs due to a software defect that may cause a loss of braking ability. The recall affects model years 2023-2024 and will be addressed via a software update. No injuries or fatalities have been reported.

Portfolio Pulse from Anan Ashraf

August 13, 2024 | 12:07 pm

URGN

UroGen Pharma announced that the latest Duration of Response (DOR) data is expected to support a New Drug Application (NDA) for UGN-102, targeting low-grade intermediate-risk non-muscle invasive bladder cancer. The company plans to complete the NDA submission soon, with a potential FDA decision as early as Q1 2025, assuming priority review.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:06 pm